{'52WeekChange': 0.897436,
 'SandP52WeekChange': None,
 'address1': '9987 Carver Road',
 'address2': 'Suite 420',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.49,
 'askSize': 1300,
 'averageDailyVolume10Day': 1460125,
 'averageVolume': 2391317,
 'averageVolume10days': 1460125,
 'beta': 2.132412,
 'beta3Year': None,
 'bid': 1.5,
 'bidSize': 900,
 'bookValue': 0.813,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cincinnati',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.55,
 'dayLow': 1.42,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.442,
 'enterpriseToRevenue': None,
 'enterpriseValue': 25631440,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '513 985 0999',
 'fiftyDayAverage': 1.2884285,
 'fiftyTwoWeekHigh': 1.62,
 'fiftyTwoWeekLow': 0.42,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 26232839,
 'forwardEps': -0.41,
 'forwardPE': -3.6097562,
 'fromCurrency': None,
 'fullTimeEmployees': 12,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.24317,
 'heldPercentInstitutions': 0.27215,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aerpio.com',
 'longBusinessSummary': 'Aerpio Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, focuses on developing and commercializing '
                        'compounds for the treatment of ocular diseases and '
                        "diabetic complications. The company's lead product "
                        'candidate is razuprotafib, a small molecule activator '
                        'of the Tie2 pathway, which completed the Phase IIb '
                        'clinical trial for the treatment of diabetic '
                        'retinopathy. It also develops ARP-1536, a humanized '
                        'monoclonal antibody that is in preclinical '
                        'development stage for the treatment of diabetic '
                        'vascular complications; GB004, a selective stabilizer '
                        'of hypoxia-inducible factor-1 alpha, which is in a '
                        'Phase 1b clinical trial for the treatment of '
                        'inflammatory bowel disease; and bispecific antibody '
                        'for the treatment for wet age-related macular '
                        'degeneration and DME through intravitreal injection. '
                        'Aerpio Pharmaceuticals, Inc. has a collaboration with '
                        'Quantum Leap Healthcare Collaborative for the '
                        'evaluation of razuprotafib in the treatment of acute '
                        'respiratory distress syndrome in adult patients with '
                        'moderate to severe COVID-19. The company is '
                        'headquartered in Cincinnati, Ohio.',
 'longName': 'Aerpio Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 60070240,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_145635340',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -18696352,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.48,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '513 985 1920',
 'previousClose': 1.48,
 'priceHint': 4,
 'priceToBook': 1.8204181,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.55,
 'regularMarketDayLow': 1.42,
 'regularMarketOpen': 1.48,
 'regularMarketPreviousClose': 1.48,
 'regularMarketPrice': 1.48,
 'regularMarketVolume': 668784,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 40588000,
 'sharesPercentSharesOut': 0.0069999998,
 'sharesShort': 282954,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 112291,
 'shortName': 'Aerpio Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0099,
 'shortRatio': 0.28,
 'startDate': None,
 'state': 'OH',
 'strikePrice': None,
 'symbol': 'ARPO',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.463,
 'twoHundredDayAverage': 0.8192302,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '8119714d-d522-3b42-9d37-59f046c7fa96',
 'volume': 668784,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aerpio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '45242'}